Nurse Practitioner, Family · Norfolk, VA
NPI
1326011974
Since 2006
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
825 Fairfax Ave, Suite 572
Norfolk, VA, 23507
Phone (757) 446-8999
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,215
148 services
Medicare patients, 2024
73
Average age 60
Drug cost, 2024
$9.1M
3,173 prescriptions
Company payments, 2025
$1,400
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rosa O Diring was code 99214 (office e&m - established), 79 times for 63 patients. In total Rosa O Diring billed 148 services in 10 codes, and Medicare paid $9,215.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-06-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 79 | 63 | $50.94 | $4,024 |
| 99213 Office E&M - Established | Office | 29 | 28 | $54.28 | $1,574 |
By year: 2022 $8,409 for 179 services; 2023 $10K for 207 services; 2024 $9,215 for 148 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rosa O Diring prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 1,059 prescriptions and refills. In total Rosa O Diring wrote 3,173 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 1,059 | 1,090 | 124 | $4.3M |
| Dovato Dolutegravir Sodium/Lamivudine | 234 | 240 | 33 | $712K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 207 | 207 | 27 | $735K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 177 | 185 | 27 | $687K |
| Descovy Emtricitabine/Tenofov Alafenam | 176 | 176 | 19 | $405K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 167 | 167 | 21 | $644K |
| Tivicay Dolutegravir Sodium | 127 | 127 | 18 | $297K |
| Prezcobix Darunavir/Cobicistat | 88 | 88 | Under 11 | $218K |
| Juluca Dolutegravir/Rilpivirine | 77 | 77 | Under 11 | $266K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 72 | 75 | Under 11 | $341K |
| Gabapentin Generic | 49 | 49 | Under 11 | $510 |
| Isentress Raltegravir Potassium | 49 | 49 | Under 11 | $99K |
| Acyclovir Generic | 42 | 50 | 11 | $861 |
| Ketoconazole Generic | 35 | 37 | 13 | $182 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 34 | 34 | Under 11 | $703 |
Brand drugs: 2,562 claims; generic drugs: 611 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rosa O Diring $1,400 ($1,400 in general payments such as food, travel and fees) from 2 companies. The largest payer was Gilead Sciences, Inc. with $755.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.